艾滋病毒风险评估工具用于识别可能受益于暴露前预防的个体:系统审查协议
Myo Minn Oo1,2, Caley Shukalek3, Teruko Kishibe4
1Division of Infectious Diseases, St Michael's Hospital, Toronto, Ontario, Canada dr.myominnoo@gmail.com.
BMJ open
|November 8, 2024
概括
本系统性审查评估了艾滋病毒风险评估工具,用于识别可能受益于暴露前预防 (PrEP) 的个人. 它综合了诊断绩效的证据,以改善艾滋病毒预防策略.
科学领域:
- 公共卫生 公共卫生
- 传染病流行病学 传染病流行病学
- 临床诊断 临床诊断 临床诊断
背景情况:
- 暴露前预防 (PrEP) 是一种关键的艾滋病毒预防策略.
- 准确识别有资格接受PrEP的个人仍然是一个挑战.
- 现有的艾滋病毒风险评估工具的性能有变化.
研究的目的:
- 系统地审查和综合艾滋病毒风险评估工具诊断性能的证据.
- 评估这些工具在预测发生HIV感染时的准确性,以获得PrEP资格.
主要方法:
- 按照PRISMA协议进行系统审查和元分析 (如有必要).
- 在MEDLINE,Embase和CINAHL数据库中进行搜索 (1998-2024).
- 使用约翰娜·布里格斯研究所批判性评估检查清单评估艾滋病毒风险工具的诊断性能.
主要成果:
- 综合各种艾滋病毒风险评估工具诊断准确性的证据.
- 为预测艾滋病毒发病率确定具有最佳性能的工具.
- 数据提取和偏差风险评估由两个独立审查员进行.
结论:
- 调查结果将为加拿大艾滋病预防准备指南的更新提供信息.
- 将指导医疗保健专业人员选择适当的艾滋病毒风险评估工具.
- 旨在改善PrEP候选人的识别,加强艾滋病毒预防工作.
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
121
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
121
Sexually Transmitted Infections
283
Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
283
Hazard Ratio
91
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
91


